1. Kux L. Draft guidance for industry on responding to unsolicited requests for off-label information about prescription drugs and medical devices. Fed Reg. 2011;76:82303–82306. https://doi.org/www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM285145.pdf?source=govdelivery.
2. Salter FJ, Kramer PF, Palmer-Shevlin NL. Pharmaceutical industry medical communications departments: regulatory and legal perils and pitfalls. Drug Information Journal. 2000;34:1009–1115.
3. Ropes & Gray, LLP. FDA issues two important documents concerning communication of off-label information. December 29, 2011. https://doi.org/www.ropesgray.com/files/Publication/774f4f3f-2cde-4080-ae83-3d0ccd10b592/Presentation/PublicationAttachment/f6fe8809-ce9f-4976-9782-4279fcb2c49e/20111229_FDA_Alert.pdf.
4. Ventola CL. Off-label drug information. FDA policy—regulation, distribution, evaluation, and related controversies. P&T Journal. 2009;34:428–449.
5. Eaton F, Scallon M. On the job off-label compliance. Pharmaceutical Executive (online). April 1, 2008. https://doi.org/www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=507986&sk=&date=&pageID=2.